Market Overview

Investigation Report on China's Imatinib Market, 2018-2022 - ResearchAndMarkets.com

Share:

The "Investigation
Report on Chinese Imatinib Market, 2018-2022"
report has been
added to ResearchAndMarkets.com's offering.

Leukemia ranks the sixth in China's cancer mortality rate, and the first
in morbidity and mortality among teenagers' malignant tumors. People
aged from 0 to 9 and over 60 are the most vulnerable to leukemia.

Imatinib is a tyrosine kinase inhibitor developed by Novartis. On May
10, 2001, Imatinib received FDA's express approval for its
"ground-breaking anti-tumor mechanism" in the trade name Gleevec. On
Dec. 23, 2002, it was approved by the FDA to be used in the first-line
treatment of chronic myeloid leukemia. So far, its use in the treatment
of chronic myeloid leukemia has been approved by over 80 countries
around the world.

The annual sales value has been growing since Imatinib entered China on
Apr. 17, 2002. It reached about CNY 700 million in 2017. At present, the
Chinese Imatinib market is dominated by three enterprises' products. As
an imported product, Novartis' Gleevec takes up the largest share.

According to the research, the price of Gleevec is so high that it is
beyond the affordability of many patients. There are three manufacturers
of generic Imatinib in China. They are Chia Tai Tianqing Pharmaceutical
Group Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd. and CSPC
Zhongqi Pharmaceutical Technology Co., Ltd. The average price of
China-made Imatinib is less than 10% of that of Gleevec. However, some
hospitals are reluctant to recommend China-made Imatinib to patients
because of its poor efficacy and low profitability. Therefore, Gleevec
has the major market share of the Imatinib legally sold in China. In
2017, its market share was 81% by sales value and 31% by sales volume.

Despite its obvious curative effect, Imatinib is much more expensive
than other drugs for chronic myeloid leukemia. Some low-income patients
in China were prosecuted for purchasing smuggled India-made Imatinib
whose price was only 5% or less of Gleevec's price in China and lower
than that of China-made generics. This case was even rearranged into the
movie Dying to Survive which has a happy ending that the low-income
patients were offered free treatment. But this is not the case in China.
More and more patients will be able to afford Imatinib with China's
economic development and residents' increasing income and purchasing
power. It is estimated that the Imatinib market will grow ever larger in
China.

Key Topics Covered:

1 Basic Concepts of Imatinib

1.1 Indications for Imatinib

1.2 Development History of Imatinib in China

1.3 Governmental Approval of Imatinib in China

2 Sales of Imatinib in China, 2013-2017

2.1 Overall Sales of Imatinib

2.2 Sales of Imatinib in Key Regions of China

2.3 Sales of Imatinib by Dosage Form

2.4 Imatinib Smuggled to China

3 Analysis of Major Imatinib Manufacturers in China

3.1 Overview of Major Competitors

3.2 Novartis

3.3 Jiangsu Hansoh Pharmaceutical Co., Ltd.

3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.5 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.

4 Prices of Imatinib in China, 2017-2018

4.1 Analysis on Average Price of Imatinib in China

4.2 Imatinib Price by Enterprise

5 Prospects of Chinese Imatinib Market, 2018-2022

5.1 Analysis on Factors Influencing Imatinib Development

5.1.1 Driving Forces

5.1.2 Unfavorable Factors

5.2 Forecast on Competition Pattern

5.3 Forecast on Market Size

Companies Mentioned

  • CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Novartis

For more information about this report visit https://www.researchandmarkets.com/research/6x5vjf/investigation?w=4

View Comments and Join the Discussion!